Full Press Release Details
Therapeutics Gives Notice of Partial
Waiver of Restrictions
Lausanne, Switzerland, September
4, 2020 - ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities,
Inc., the lead book-running managers in the Company's recent initial public offering, are releasing a lock-up restriction
with respect to 105,000 common shares held by A.T. Holdings II S rl, an affiliate of Peter B. Corr and Stephen Evans-Freke
who are members of the Company's board of directors, as part of a block trade of common shares to HPWH TH AG. Both A.T.
Holdings II S rl and HPWH TH AG are long-term investors who continue to hold significant interests in the Company and are
represented on the Company's board of directors. The release will take effect on September 10, 2020, and the shares may be
sold on or after such date.
This press release is not an
offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities
may not be offered or sold in the United States absent registration or an exemption from registration under the United States
Securities Act of 1933, as amended.
About ADC Therapeutics
Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization
of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The
Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD)
technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and
substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline
of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical
trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in
tesirine (Lonca, formerly ADCT-402), the Company's lead product candidate, has been evaluated in a 145-patient pivotal Phase
2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall
response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company's
second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed
or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The Company is
also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.
Therapeutics is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company
on Twitter and LinkedIn.
This press release contains statements
that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release,
including statements regarding our future results of operations and financial position, business strategy, product
candidates, research pipeline,
ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs,
timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements.
Forward-looking statements are based on our management's beliefs and assumptions and on information currently available
to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those
expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation
or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations
or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable
law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Tel.: +1 917-288-7023
Tel: +41 (0) 43 268 3231
Tel.: +1 973-415-8838